Copy Link Print Information

Temuterkib

(Synonyms: LY3214996)
35 Cited Publications
Avis client

Based on 35 publication(s) in Google Scholar

Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté: 99.93%
  • CAS No.: 1951483-29-6
  • Formule: C22H27N7O2S
  • Masse moléculaire:453.56
  • Stockage:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Temuterkib Chemical Structure
    Temuterkib Chemical Structure
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
CAS No.: 1951483-29-6
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Temuterkib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Pureté et documentation
  • Références
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Temuterkib

More
Customer Validation & Images
IPWBBio/Physico-chemical AssayIF
  • WB
  • Bio/Physico-chemical Assay
  • WB
  • IF
  • IP
  • IP
  • WB

Voir tous les produits spécifiques à Isoform ERK

More
Keywords
MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Temuterkib Chemical Structure
    Temuterkib Chemical Structure
    1/16
  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar;21(3):565-582. [Abstract]

    Customer Validation
     Western blot analysis of sgCtrl, sgUSP13#1 or sgUSP13#2 A549 cell lysates treated with DMSO or Temuterkib (LY3214996, 10 μM, 24 h) and probed with the indicated antibodies.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Mar 5;11(10):5045-5060. [Abstract]

    Customer Validation
     Cells were pre-treated with DMSO, 3-NC (20 µM), Temuterkib (LY3214996, 2 µM), or 3-NC (20 µM) + Temuterkib (LY3214996, 2 µM) for 2h, respectively; then Ca2+ mobilization in Fura-2-loaded cells respectively upon FGF19 stimulation were measured and expressed as means ± SEM of 12 independent cells each group.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Mar 5;11(10):5045-5060. [Abstract]

    Customer Validation
     Subcellular location of NFATc2 after FGF19 treatment: Huh-7 NCSCs were pre-treated with DMSO, BLU9931 (100 nM), 3-NC (20 µM), Temuterkib (LY3214996, 2 µM), 3-NC (20 µM) + Temuterkib (LY3214996, 2 µM), SKF96365 (5 µM), and FK506 (50 nM) for 2h, respectively; then treated with FGF19 (100 ng/ml) for 4h.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Mar 5;11(10):5045-5060. [Abstract]

    Customer Validation
     Subcellular location of NFATc2 after FGF19 treatment: Huh-7 NCSCs were pre-treated with DMSO, BLU9931 (100 nM), 3-NC (20 µM), Temuterkib (LY3214996, 2 µM), 3-NC (20 µM) + Temuterkib (LY3214996, 2 µM), SKF96365 (5 µM), and FK506 (50 nM) for 2h, respectively; then treated with FGF19 (100 ng/ml) for 4h.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 Sep 30;5(1):197. [Abstract]

    Customer Validation
     Endogenous and exogenous LSH were respectively immunoprecipitated from A549 and 293T cells after treatment with the MAPK1/2 inhibitor Temuterkib for the indicated time, and then IB assay was carried out to detect the phosphorylated LSH with anti-phosphoserine antibody.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 Sep 30;5(1):197. [Abstract]

    Customer Validation
     IP followed by IB assay in PC9 cell lines stably expressing LSH after treatment with the MAPK1/2 inhibitor Temuterkib for the indicated time.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2019 May;110(5):1746-1759. [Abstract]

    Customer Validation
     Cells are treated with RA in the presence or absence of the Erk1/2 inhibitor LY3214996, phospho-Erk1/2, Erk1/2, phospho-JNK, JNK, phospho-c-Jun, c-Jun, total and cleaved PARP, phospho-STAT3S727, and STAT3 are analyzed.

  • Temuterkib